Supplementary Materials

This PDF file includes:

  • Fig. S1. Overview of clinical and genetic parameters in PDO cohorts.
  • Fig. S2. Overview of the irinotecan PDO-patient cohort.
  • Fig. S3. Development and cross-validation of an irinotecan classifier.
  • Fig. S4. Overview of the 5-FU–irinotecan PDO-patient cohort.
  • Fig. S5. Development and cross-validation of a 5-FU–irinotecan classifier.
  • Fig. S6. Overview of the 5-FU–oxaliplatin PDO-patient cohort.
  • Fig. S7. 5-FU–oxaliplatin drug responses of synchronous and paired metastases.
  • Fig. S8. The effects of clinical and genetic parameters on patients and PDO responses.
  • Table S1. Characteristics and clinical history of all patients included in the TUMOROID study.
  • Table S2. Genetic and pathological characteristics of patients in the TUMOROID study.
  • Table S3. Overview of the three cohorts and previous treatments and procedures.

[Download PDF]